Back to top
more

Alignment Healthcare (ALHC)

(Delayed Data from NSDQ)

$12.97 USD

12.97
3,566,563

-0.81 (-5.88%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $12.96 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?

by Zacks Equity Research

Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?

by Indrajit Bandyopadhyay

CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.

Zacks Equity Research

Alignment Healthcare (ALHC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Alignment Healthcare (ALHC) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +200.00% and +5.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alignment Healthcare (ALHC) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Alignment Healthcare (ALHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.

Zacks Equity Research

Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?

by Zacks Equity Research

Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.

Zacks Equity Research

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Zacks Equity Research

Compared to Estimates, Alignment Healthcare (ALHC) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Alignment Healthcare (ALHC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 58.33% and 4.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

All You Need to Know About Alignment Healthcare (ALHC) Rating Upgrade to Buy

by Zacks Equity Research

Alignment Healthcare (ALHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Zacks Equity Research

Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Alignment Healthcare (ALHC) Surges 6.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alignment Healthcare (ALHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks Equity Research

Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYX

Zacks Equity Research

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Zacks Equity Research

Is Alignment Healthcare (ALHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alignment Healthcare (ALHC) and Fresenius (FMS) have performed compared to their sector so far this year.

Zacks Equity Research

Compared to Estimates, Alignment Healthcare (ALHC) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Alignment Healthcare (ALHC) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 11.11% and 3.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insights Into Alignment Healthcare (ALHC) Q4: Wall Street Projections for Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Alignment Healthcare (ALHC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Equity Research

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYX

Zacks Equity Research

GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Compared to Estimates, Alignment Healthcare (ALHC) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Alignment Healthcare (ALHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Alignment Healthcare (ALHC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 0% and 4.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?